Dabur India shares drop 3% as arms face lawsuits in Canada,

The settlement or verdict conclusion cannot be known, according to Dabur India. Any eventual claim settlement sum, according to that statement, is neither probable nor estiable.

Any ultimate claim settlement sum is neither probable nor estivable at this point in the legal process, according to Dabur India. — Dabur India: Currently, there are about 5,400 lawsuits in which Dabur India, which manufactures the Namaste, Dermoviva, and DINTL brands, is named as a defendant alongside some other members of the industry.

Dabur India’s stock fell 3% on Thursday after three of its companies, Namaste Laboratories, Dermoviva Skin Essentials, and Dabur International, were sued in Canadian and American federal and state courts.

The lawsuits were brought about chemicals found in hair relaxer products that were said to have given consumers ovarian cancer, uterine cancer, and other health problems.

Before the United States District Court for the Northern District of Illinois, the federal cases were merged as multi-district litigation, or MDL.

According to the FMCG company, the lawsuits are currently in the pleadings and early discovery stages of litigation, which means the parties are debating whether the plaintiffs’ complaints are sufficient and, in some cases, exchanging demands for information and documents.

The statement continued, “There are various motions pending as well,” stating that it was impossible to predict how a settlement or verdict would affect the parties’ finances.